Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)
Francesco Zappa(Friedrich Schiller University Jena), Miklos Pless(Ontario Institute for Cancer Research), C. Droege(University Hospital of Basel), Karin Ribi, Daniel Rauch(Washington University in St. Louis), Rolf A. Stahel(International Breast Cancer Study Group), Thomas Heß(Bavarian Research Institute for Digital Transformation), Roger von Moos(Kantonsspital Graubünden), Adrian F. Ochsenbein(University of Bern), Elisabeth Oppliger Leibundgut(University Hospital of Bern), Michael Mayer(Swiss Group For Clinical Cancer Research), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Peter Brauchli(University of St.Gallen), Patrizia Froesch(Institute of Oncology Research), Petra Schmid(Kantonsspital Aarau), Lukas Bubendorf(University of Basel), Susanne Crowe(Swiss Group For Clinical Cancer Research), Daniel Betticher
Cited by 32
Related Papers
Tissue microarrays for high-throughput molecular profiling of tumor specimens
|Nature Medicine|1998|4.1k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k